Myeloproliferative Neoplasms Clinical Trial
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis.
Data from approximately 1000 participants will be collected. No participants will be enrolled in this study.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks.
There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)].
Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
- Having received MF treatment in a clinical trial setting.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 65 Locations for this study
Birmingham Alabama, 35233, United States
West Hills California, 91307, United States
Boston Massachusetts, 02115, United States
Canton Ohio, 44718, United States
La Plata Buenos Aires, 1900, Argentina
Ciudad Autonoma Buenos Aires Ciuadad Autonoma De Buenos Aires, 1199, Argentina
Ciudad Autonoma de Buenos Aire Ciuadad Autonoma De Buenos Aires, 1114, Argentina
Douglas Queensland, 4814, Australia
Adelaide South Australia, 5000, Australia
Murdoch Western Australia, 6150, Australia
Perth Western Australia, 6000, Australia
São Paulo Sao Paulo, 05652, Brazil
Sao Paulo , 05403, Brazil
Vancouver British Columbia, V6Z 1, Canada
Halifax Nova Scotia, B3H 1, Canada
Hamilton Ontario, L8V 1, Canada
Toronto Ontario, M5G 2, Canada
Levis Quebec, G6V 3, Canada
Montreal Quebec, H1T 2, Canada
Montreal Quebec, H3T 1, Canada
Baranquilla Atlantico, 08001, Colombia
Bogota DC Cundinamarca, 11122, Colombia
Bogota Cundinamarca, 11011, Colombia
Cali , 76004, Colombia
Medellin , 50034, Colombia
Athens Attiki, 11527, Greece
Athens Attiki, 12462, Greece
Heraklion Kriti, 71500, Greece
Alexandroupolis , 68100, Greece
Athens , 10676, Greece
Ioannina , 45500, Greece
Piraeus , 18737, Greece
RION Patras Achaia , 26504, Greece
Cona Ferrara, 44124, Italy
Rome Lazio, 00168, Italy
Perugia Umbria, 06129, Italy
Bologna , 40138, Italy
Brescia , 25123, Italy
Milan , 20122, Italy
Novara , 28100, Italy
Palermo , 90127, Italy
Varese , 21100, Italy
Viterbo , 01100, Italy
Ciudad de México Ciudad De Mexico, 06720, Mexico
Monterrey Nuevo Leon, 64610, Mexico
Ciudad de Mexico , 06720, Mexico
Warsaw Mazowieckie, 01-30, Poland
Gdańsk Pomorskie, 80-33, Poland
Orzesze , 43-18, Poland
Łódź , 90-71, Poland
Coimbra , 3000-, Portugal
Lisboa , 1649-, Portugal
Porto , 4200-, Portugal
Brașov Brasov, 50015, Romania
Bucharest , 92520, Romania
Bucuresti , 02012, Romania
Cluj Napoca , 40001, Romania
Kaohsiung , 807, Taiwan
Taipei City , 100, Taiwan
Ankara , 06010, Turkey
Ankara , 06230, Turkey
Diyarbakir , 21200, Turkey
Edirne, Istanbul , 22030, Turkey
Istanbul , 34214, Turkey
Izmir , 35040, Turkey
Malatya , 44280, Turkey
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.